Shire PLC (LON:SHP) had its price objective cut by HSBC from GBX 5,250 ($68.53) to GBX 5,200 ($67.88) in a report released on Wednesday. They currently have a hold rating on the biopharmaceutical company’s stock.
A number of other analysts have also recently issued reports on the company. Citigroup Inc. reissued a buy rating on shares of Shire PLC in a research note on Monday, September 19th. Royal Bank Of Canada reissued an outperform rating on shares of Shire PLC in a research note on Friday, July 22nd. Goldman Sachs Group Inc. reissued a buy rating and set a GBX 6,300 ($82.23) target price on shares of Shire PLC in a research note on Tuesday, July 12th. BNP Paribas reissued an outperform rating and set a GBX 5,700 ($74.40) target price on shares of Shire PLC in a research note on Tuesday, July 26th. Finally, Jefferies Group increased their target price on Shire PLC from GBX 5,150 ($67.22) to GBX 6,050 ($78.97) and gave the stock a buy rating in a research note on Monday, June 6th. One analyst has rated the stock with a sell rating, one has given a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of Buy and an average target price of GBX 5,828 ($76.07).
Shares of Shire PLC (LON:SHP) opened at 5040.00 on Wednesday. Shire PLC has a 52 week low of GBX 2,707.19 and a 52 week high of GBX 5,377.00. The stock has a 50 day moving average of GBX 4,983.22 and a 200-day moving average of GBX 4,511.67. The firm’s market capitalization is GBX 34.41 billion.
The firm also recently declared a dividend, which will be paid on Friday, October 7th. Shareholders of record on Thursday, September 8th will be issued a dividend of GBX 3.51 ($0.05) per share. This represents a yield of 0.07%. The ex-dividend date of this dividend is Thursday, September 8th.
In other Shire PLC news, insider Dominic Blakemore purchased 133 shares of the business’s stock in a transaction on Friday, September 30th. The stock was acquired at an average price of GBX 5,010 ($65.40) per share, with a total value of £6,663.30 ($8,697.69).
Shire PLC Company Profile
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.